Downloaded in Aug 2019

Total Page:16

File Type:pdf, Size:1020Kb

Downloaded in Aug 2019 ARTICLE https://doi.org/10.1038/s41467-021-24473-2 OPEN IL-15 and PIM kinases direct the metabolic programming of intestinal intraepithelial lymphocytes Olivia J. James1, Maud Vandereyken1, Julia M. Marchingo 2, Francois Singh1, Susan E. Bray3, Jamie Wilson4, ✉ Andrew G. Love1 & Mahima Swamy 1 1234567890():,; Intestinal intraepithelial lymphocytes (IEL) are an abundant population of tissue-resident T cells that protect and maintain the intestinal barrier. IEL respond to epithelial cell-derived IL-15, which is complexed to the IL-15 receptor α chain (IL-15/Rα). IL-15 is essential both for maintaining IEL homeostasis and inducing IEL responses to epithelial stress, which has been associated with Coeliac disease. Here, we apply quantitative mass spectrometry to IL-15/Rα- stimulated IEL to investigate how IL-15 directly regulates inflammatory functions of IEL. IL-15/ Rα drives IEL activation through cell cycle regulation, upregulation of metabolic machinery and expression of a select repertoire of cell surface receptors. IL-15/Rα selectively upregu- lates the Ser/Thr kinases PIM1 and PIM2, which are essential for IEL to proliferate, grow and upregulate granzyme B in response to inflammatory IL-15. Notably, IEL from patients with Coeliac disease have high PIM expression. Together, these data indicate PIM kinases as important effectors of IEL responses to inflammatory IL-15. 1 MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK. 2 Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK. 3 NHS Research Scotland, Tayside Tissue Biorepository, University of Dundee, Dundee, UK. 4 Department of ✉ Pathology, NHS Tayside, Ninewells Hospital, Dundee, UK. email: [email protected] NATURE COMMUNICATIONS | (2021) 12:4290 | https://doi.org/10.1038/s41467-021-24473-2 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24473-2 ntraepithelial lymphocytes (IEL) are a specialised lymphoid Here, we investigate the intrinsic effects of exposure to elevated compartment in the intestinal epithelium, comprising a het- levels of IL-15 on IEL. We take a systematic unbiased approach I 1 fi erogeneous population of T lymphocytes . IEL express either using high-resolution quantitative proteomics to de ne the global the αβ T cell antigen receptor (TCR) or the γδ TCR, alongside changes induced in purified TCRγδCD8αα, TCRαβCD8αα and TCR co-receptors CD8αβ or CD8αα and to a lesser extent CD4 TCRαβCD8αβ IEL subpopulations after 24 h exposure to IL-15. (+/−). The most prevalent IEL subsets within the epithelium of the Our data show how IL-15 regulates the activation status of IEL mouse small intestine are those expressing TCRγδ and CD8αα through the upregulation of various activating and inhibitory (TCRγδCD8αα), which account for ~50% of the total IEL pool, receptors, biosynthetic and bioenergetic activation, and induction with the remaining mostly being TCRαβCD8αβ or TCRαβCD8αα- of proliferation. Importantly, these data reveal a critical role for expressing cells. In human guts, TCRαβCD8αβ and TCRαβCD4 the proto-oncogenes PIM1 and PIM2 kinases in IL-15-induced make-up the majority of IEL, with TCRγδ IEL contributing proliferation, growth, and acquisition of effector function in IEL. <5–20% of the IEL compartment2. IEL are constantly exposed to commensal bacteria, dietary antigens, and potential pathogens at the intestinal epithelium, and are tasked with responding to epi- Results thelial stress and protecting the intestinal barrier from external Proteome profiling reveals distinct features of IL-15/Rα sti- insults. How IEL get activated is a matter of debate; but IEL do not mulated IEL. Here, we used quantitative label-free high-resolu- solely depend on TCR stimulation for their activation, rather, tion mass spectrometry to explore how IL-15 shapes the signals from the microenvironment are important for commu- proteome of the main mouse IEL subsets: TCRαβCD8αβ, nicating compromised barrier integrity to the surrounding IEL TCRαβCD8αα and TCRγδCD8αα (Supplementary Fig. 1a). and eliciting an effective immune response. One such signal is the Importantly, we used IL-15/Rα complexes to better mimic the γ γ common -chain ( c) family cytokine IL-15. trans-presentation of IL-15 by IEC, and because it is more IL-15 is produced by a wide range of cells including non- representative of physiological conditions17,18. For IL-15-induced hematopoietic cells such as intestinal epithelial cells (IEC) and its activation, IEL were treated for 24 h with 100 ng/mL IL-15/Rα expression is elevated in the gut microenvironment during tissue (3.4 nM), based on pSTAT5 induction (Supplementary Fig. 1b) stress or infection3. IL-15 is commonly presented to surrounding and higher survival (Fig. 1a) observed at this concentration. IEL in a cell contact-dependent manner, known as trans-pre- Untreated controls were derived directly ex vivo, as IEL do not sentation, by IEC expressing IL-15 bound to the high-affinity IL- survive well in culture with low concentrations, or in complete 15 receptor α subunit (IL-15Rα)4. IL-15/Rα interacts with the β absence of IL-15 (Fig. 1a). γ fi fi (CD122) and c subunits present on the surface of IEL, initiating We identi ed and quanti ed >7500 proteins in the total dataset JAK/STAT-mediated signalling events that alter lymphocyte (4 biological replicates/population; ±IL-15/Rα), providing high- function5. It is well established that IEL require IL-15 for their resolution quantitative proteomes of three developmentally survival in the small intestine6, and development and maturation diverse IEL populations. Intensities were converted into estimated of CD8αα IEL can be rescued in IL-15Rα−/− mice by restoring protein copy number per cell using the proteomic histone ruler IL-15Rα expression to the intestinal epithelium4. method19,20. Both intensities and copy numbers showed good IL-15 impacts more than just IEL survival. IL-15 induces correlation between replicates and subsets, despite their differ- proliferation and cytolytic effector function in human IEL ences in ontogeny. All IEL subsets had similar protein content in vitro7. Importantly, elevated intestinal IL-15 expression is (~40–50 pg/cell), and this was not significantly changed by IL-15 associated with increased numbers of cytotoxic IEL in the small (Fig. 1b). These data indicate that different IEL subsets are similar intestine of Coeliac disease (CeD) patients8, attributed to IL-15- in their protein make-up and overall protein abundance driven survival and proliferative expansion of IEL9,10. CeD is an (Supplementary Fig. 1c, d). autoimmune enteropathy whereby genetically susceptible indivi- To investigate how IL-15 differentially altered the proteomic duals have an adverse reaction to gluten, causing immune- landscape of each subset, we calculated the fold change in mediated damage to the small intestine. IEL derived from patients expression of proteins (IL-15-treated vs untreated) and found that with CeD have elevated expression of activating NK cell receptors IL-15 largely drove the upregulation of proteins in all IEL subsets such as NKG2D and CD94 and expand massively in response to (Fig. 1c and Supplementary Data 3). Interestingly, IL-15 had the elevated levels of IL-159,11. These findings suggest that regulation strongest impact on TCRαβCD8αβ IEL, with >600 proteins being of epithelial expression of IL-15 is a key mechanism by which IEL significantly upregulated >2-fold, approximately twice as many as activity is controlled. Thus, for IEL to utilise IL-15 as a survival in TCRαβCD8αα and TCRγδCD8αα IEL. This was surprising, as stimulus but also respond to rising levels of IL-15 as a ‘danger TCRαβCD8αβ IEL expressed the lowest copies of IL2Rβ (CD122), signal’, IEL responses to IL-15 must be tightly controlled. How- the IL-15 receptor subunit necessary for signal transduction ever, the mechanism by which IL-15 mediates IEL function is downstream of IL-15 (Supplementary Fig. 1e). However, the poorly understood. phosphorylation of STAT5 both ex vivo and in response to IL-15/ Much of the data we have on effects of IL-15 on IEL have been Rα stimulation was comparable in all three subsets (Supplemen- derived from CeD patients and from ‘healthy’ IEL obtained from tary Fig. 1f). These data suggest that CD122 levels on oesophagus-gastro-duodenoscopies for non-CeD complaints, or TCRαβCD8αβ IEL are sufficient to activate downstream signal- from gastric bypasses for morbidly obese patients11–13. Due to the ling at a similar level to that seen in the other IEL subsets. cell contact-dependent mechanism of IL-15 presentation, it is To identify shared IL-15 targets in IEL, we next asked which likely that IEL from CeD patients, and indeed, other entero- proteins were commonly regulated by IL-15 among IEL subsets. pathies, receive additional stress signals from the IEC that they IL-15/Rα stimulation led to the downregulation of relatively few are in contact with in vivo. For example, the stress-induced proteins, with only 5 being significantly downregulated >2-fold in NKG2D ligands, MIC-A and MIC-B, are elevated on damaged all three IEL subsets (Fig. 1d, Supplementary Data 1). On the IEC in CeD, and can activate IEL11,12,14. IEL are also exposed to other hand, we identified 95 proteins that were significantly IL-21 and interferons in CeD15,16, and it is unclear how many of upregulated >2-fold in all IEL subsets, and >240 proteins these factors are present in so-called healthy human controls. significantly
Recommended publications
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Supplementary Table S5. Differentially Expressed Gene Lists of PD-1High CD39+ CD8 Tils According to 4-1BB Expression Compared to PD-1+ CD39- CD8 Tils
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Supplementary Table S5. Differentially expressed gene lists of PD-1high CD39+ CD8 TILs according to 4-1BB expression compared to PD-1+ CD39- CD8 TILs Up- or down- regulated genes in Up- or down- regulated genes Up- or down- regulated genes only PD-1high CD39+ CD8 TILs only in 4-1BBneg PD-1high CD39+ in 4-1BBpos PD-1high CD39+ CD8 compared to PD-1+ CD39- CD8 CD8 TILs compared to PD-1+ TILs compared to PD-1+ CD39- TILs CD39- CD8 TILs CD8 TILs IL7R KLRG1 TNFSF4 ENTPD1 DHRS3 LEF1 ITGA5 MKI67 PZP KLF3 RYR2 SIK1B ANK3 LYST PPP1R3B ETV1 ADAM28 H2AC13 CCR7 GFOD1 RASGRP2 ITGAX MAST4 RAD51AP1 MYO1E CLCF1 NEBL S1PR5 VCL MPP7 MS4A6A PHLDB1 GFPT2 TNF RPL3 SPRY4 VCAM1 B4GALT5 TIPARP TNS3 PDCD1 POLQ AKAP5 IL6ST LY9 PLXND1 PLEKHA1 NEU1 DGKH SPRY2 PLEKHG3 IKZF4 MTX3 PARK7 ATP8B4 SYT11 PTGER4 SORL1 RAB11FIP5 BRCA1 MAP4K3 NCR1 CCR4 S1PR1 PDE8A IFIT2 EPHA4 ARHGEF12 PAICS PELI2 LAT2 GPRASP1 TTN RPLP0 IL4I1 AUTS2 RPS3 CDCA3 NHS LONRF2 CDC42EP3 SLCO3A1 RRM2 ADAMTSL4 INPP5F ARHGAP31 ESCO2 ADRB2 CSF1 WDHD1 GOLIM4 CDK5RAP1 CD69 GLUL HJURP SHC4 GNLY TTC9 HELLS DPP4 IL23A PITPNC1 TOX ARHGEF9 EXO1 SLC4A4 CKAP4 CARMIL3 NHSL2 DZIP3 GINS1 FUT8 UBASH3B CDCA5 PDE7B SOGA1 CDC45 NR3C2 TRIB1 KIF14 TRAF5 LIMS1 PPP1R2C TNFRSF9 KLRC2 POLA1 CD80 ATP10D CDCA8 SETD7 IER2 PATL2 CCDC141 CD84 HSPA6 CYB561 MPHOSPH9 CLSPN KLRC1 PTMS SCML4 ZBTB10 CCL3 CA5B PIP5K1B WNT9A CCNH GEM IL18RAP GGH SARDH B3GNT7 C13orf46 SBF2 IKZF3 ZMAT1 TCF7 NECTIN1 H3C7 FOS PAG1 HECA SLC4A10 SLC35G2 PER1 P2RY1 NFKBIA WDR76 PLAUR KDM1A H1-5 TSHZ2 FAM102B HMMR GPR132 CCRL2 PARP8 A2M ST8SIA1 NUF2 IL5RA RBPMS UBE2T USP53 EEF1A1 PLAC8 LGR6 TMEM123 NEK2 SNAP47 PTGIS SH2B3 P2RY8 S100PBP PLEKHA7 CLNK CRIM1 MGAT5 YBX3 TP53INP1 DTL CFH FEZ1 MYB FRMD4B TSPAN5 STIL ITGA2 GOLGA6L10 MYBL2 AHI1 CAND2 GZMB RBPJ PELI1 HSPA1B KCNK5 GOLGA6L9 TICRR TPRG1 UBE2C AURKA Leem G, et al.
    [Show full text]
  • 32-13307: LY9 Human Description Product Info
    9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 32-13307: LY9 Human Lymphocyte Antigen 9, Signaling Lymphocytic Activation Molecule 3, Cell Surface Molecule Ly-9, SLAM Alternative Name : Family Member 3, SLAMF3, CD229 Antigen, CD229, Hly9, MLY9, LY9. Description Source: Sf9, Baculovirus cells. Sterile filtered colorless solution. Lymphocyte Antigen 9, also known as LY9 is a member of the SLAM family of immunomodulatory receptors, LY9 interacts with the adaptor molecule SAP . LY9 plays a part in adhesion reactions between T lymphocytes and accessory cells via homophilic interaction. LY9 promotes T-cell differentiation into a helper T-cell Th17 phenotype which leads to increased IL-17 secretion; the costimulatory activity requires SH2D1A. Furthermore it also promotes recruitment of RORC to the IL-17 promoter. LY9 is implicated in the maintenance of peripheral cell tolerance through serving as a negative regulator of the immune response. LY9 disables autoantibody responses as well as inhibits IFN-gamma secretion by CD4(+) T-cells. Moreover, LY9 negatively regulate the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells. Systemic Lupus Erythematosus is one of the diseases which are associated with LY9. LY9 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 416 amino acids (48-454 aa) and having a molecular mass of 45.9kDa (Migrates at 40-57kDa on SDS-PAGE under reducing conditions).LY9 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
    [Show full text]
  • Characteristics of B Cell-Associated Gene Expression in Patients With
    MOLECULAR MEDICINE REPORTS 13: 4113-4121, 2016 Characteristics of B cell-associated gene expression in patients with coronary artery disease WENWEN YAN*, HAOMING SONG*, JINFA JIANG, WENJUN XU, ZHU GONG, QIANGLIN DUAN, CHUANGRONG LI, YUAN XIE and LEMIN WANG Department of Internal Medicine, Division of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China Received May 19, 2015; Accepted February 12, 2016 DOI: 10.3892/mmr.2016.5029 Abstract. The current study aimed to identify differentially with the two other groups. Additionally the gene expression expressed B cell-associated genes in peripheral blood mono- levels of B cell regulatory genes were measured. In patients nuclear cells and observe the changes in B cell activation at with AMI, CR1, LILRB2, LILRB3 and VAV1 mRNA expres- different stages of coronary artery disease. Groups of patients sion levels were statistically increased, whereas, CS1 and IL4I1 with acute myocardial infarction (AMI) and stable angina (SA), mRNAs were significantly reduced compared with the SA and as well as healthy volunteers, were recruited into the study control groups. There was no statistically significant difference (n=20 per group). Whole human genome microarray analysis in B cell-associated gene expression levels between patients was performed to examine the expression of B cell-associated with SA and the control group. The present study identified the genes among these three groups. The mRNA expression levels downregulation of genes associated with BCRs, B2 cells and of 60 genes associated with B cell activity and regulation were B cell regulators in patients with AMI, indicating a weakened measured using reverse transcription-quantitative polymerase T cell-B cell interaction and reduced B2 cell activation during chain reaction.
    [Show full text]
  • Anti-Mouse CD84 APC Catalog Number: 17‐0841 Also Known As:SLAMF5 RUO: for Research Use Only
    Anti-Mouse CD84 APC Catalog Number: 17‐0841 Also Known As:SLAMF5 RUO: For Research Use Only Left: Lineagelo C57BL/6 bone marrow cells were stained with Anti‐ Mouse Ly‐6A/E (Sca‐1) PE (cat. 12‐5981) and 0.5 µg of Anti‐Mouse CD84 APC. Right: Staining of mouse splenocytes with 0.5 µg of Armenian Hamster IgG Isotype Control APC (cat. 17‐4888) (blue histogram) or 0.5 µg of Anti‐Mouse CD84 APC (purple histogram). Total viable cells were used for analysis. Product Information Contents: Anti‐Mouse CD84 APC Formulation: aqueous buffer, 0.09% sodium azide, may contain Catalog Number: 17‐0841 carrier protein/stabilizer Clone: mCD84.7 Temperature Limitation: Store at 2‐8°C. Do not freeze. Light Concentration: 0.2 mg/mL sensitive material. Host/Isotype: Armenian Hamster IgG1 Batch Code: Refer to Vial Use By: Refer to Vial Description This mCD84.7 monoclonal antibody reacts with mouse CD84, a 64‐ to 82‐kDa member of the SLAM family of Ig receptors. CD84 is a highly glycosylated single transmembrane receptor. Expressed in B and T cells, monocytes, platelets, and thymocytes, this receptor was recently found to also be expressed on Sca‐1+c‐kit+Lin‐ mouse bone marrow hematopoietic stem cells. CD84 has been reported to bind itself homophilically to promote IFNγ secretion and act as a costimulatory molecule. Once phosphorylated, the cytoplasmic tail binds signaling lymphocyte activation molecule‐associated protein (SAP). Applications Reported This mCD84.7 antibody has been reported for use in flow cytometric analysis. Applications Tested This mCD84.7 antibody has been tested by flow cytometric analysis of mouse splenocytes and bone marrow.
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • Anti-CD18 / LFA1 Beta Antibody (ARG41484)
    Product datasheet [email protected] ARG41484 Package: 100 μl anti-CD18 / LFA1 beta antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes CD18 / LFA1 beta Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name CD18 / LFA1 beta Antigen Species Human Immunogen Recombinant protein of Human CD18 / LFA1 beta. Conjugation Un-conjugated Alternate Names MF17; LAD; CD antigen CD18; MFI7; MAC-1; Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; LCAMB; Integrin beta-2; Complement receptor C3 subunit beta; LFA-1; CD18 Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse thymus Calculated Mw 85 kDa Observed Size ~ 98 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw www.arigobio.com 1/3 cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol ITGB2 Gene Full Name integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) Background This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers.
    [Show full text]
  • Single Cell RNA-Seq and Mass Cytometry Reveals a Novel and a Targetable Population Of
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.04.425268; this version posted January 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Single Cell RNA-seq and Mass Cytometry Reveals a Novel and a Targetable Population of Macrophages in Idiopathic Pulmonary Fibrosis Authors: 5 Ayaub EA4*, Poli S2*, Ng J4, Adams T3, Schupp J3, Quesada-Arias L2, Poli F1, Cosme C3, Robertson M6 , Martinez-Manzano J4, Liang X1,4, Villalba J5, Lederer J4, Chu SG4, Raby BA4, Washko G4, Coarfa C6, Perrella MA4, El-Chemaly S4, Kaminski N3, Rosas IO1 Author Affiliations: 10 1 Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA 2 Mount Sinai Medical Center, Division of Internal Medicine, Miami Beach, FL, USA. 3 Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA 4Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 15 5 Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 6 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA 20 *These authors contributed equally to the work 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.04.425268; this version posted January 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Author Contributions: EA, SP, IOR, and NK conceptualized the study.
    [Show full text]
  • Rabbit Anti-Phospho-CD18-SL10462R-FITC
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-Phospho-CD18 SL10462R-FITC Product Name: Anti-Phospho-CD18 (Thr758)/FITC Chinese Name: FITC标记的磷酸化整合素β2/Integrin β2抗体 CD18 (Phospho Thr758); CD18 (Phospho-Thr758); CD18 (Phospho T758); p-CD18 (T758); p-CD18 (Thr758); Integrin beta 2; 95 subunit beta; CD 18; CD18; Cell surface adhesion glycoprotein LFA 1/CR3/P150,959 beta subunit precursor); Cell surface adhesion glycoproteins LFA 1/CR3/p150,95 subunit beta; Cell surface adhesion glycoproteins LFA-1/CR3/p150; Complement receptor C3 beta subunit; Complement Alias: receptor C3 subunit beta; Integrin beta chain beta 2; Integrin beta-2; Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); ITB2_HUMAN; ITGB2; LAD; LCAMB; Leukocyte associated antigens CD18/11A, CD18/11B, CD18/11C; Leukocyte cell adhesion molecule CD18; LFA 1; LFA1; Lymphocyte function associated antigen 1; MAC 1; MAC1; MF17; MFI7; OTTHUMP00000115278; OTTHUMP00000115279; OTTHUMP00000115280; OTTHUMP00000115281; OTTHUMP00000115282. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Chicken,Dog,Pig,Cow,Horse,Rabbit,Sheep,Guinea Pig, Flow-Cyt=1:50-200ICC=1:50-200IF=1:50-200www.sunlongbiotech.com Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 82kDa Form: Lyophilized or Liquid Concentration: 1mg/ml KLH conjugated synthesised phosphopeptide derived from human CD18 around the immunogen: phosphorylation site of Thr758 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year.
    [Show full text]